Trials / Unknown
UnknownNCT05349045
Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer
Containing Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Anti-tumor Treatment of Chinese Patients With Unresectable Locally Advanced / Recurrent or Metastatic Esophageal Cancer: a Real World Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- The First Affiliated Hospital of Zhengzhou University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The combination of an anti-PD-1/PD-L1 antibody with an angiogenesis inhibitor has shown efficacy in many cancers.The purpose of this study is to confirm that the combination of these two drugs can benefit patients with advanced esophageal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor | This is an observational study |
Timeline
- Start date
- 2022-05-05
- Primary completion
- 2024-05-05
- Completion
- 2025-05-05
- First posted
- 2022-04-27
- Last updated
- 2022-04-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05349045. Inclusion in this directory is not an endorsement.